Clinical Trial Update: Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update assessing antibody persistence 18 months after vaccination with the V72P10 candidate meningococcal vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• V72P10

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease, Meningococcal Meningitis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2014-03-11